Profile of blonanserin for the treatment of schizophrenia
Received 18 February 2013
Accepted for publication 26 February 2013
Published 29 April 2013 Volume 2013:9 Pages 587—594
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Tomomi Tenjin, Seiya Miyamoto, Yuriko Ninomiya, Rei Kitajima, Shin Ogino, Nobumi Miyake, Noboru Yamaguchi
Department of Neuropsychiatry, St Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
Abstract: Blonanserin was developed as an antipsychotic drug in Japan and approved for the treatment of schizophrenia. It belongs to a series of 4-phenyl-2-(1-piperazinyl)pyridines and acts as an antagonist at dopamine D2, D3, and serotonin 5-HT2A receptors. Blonanserin has low affinity for 5-HT2C, adrenergic α1, histamine H1, and muscarinic M1 receptors, but displays relatively high affinity for 5-HT6 receptors. In several short-term double-blind clinical trials, blonanserin had equal efficacy as haloperidol and risperidone for positive symptoms in patients with chronic schizophrenia and was also superior to haloperidol for improving negative symptoms. Blonanserin is generally well tolerated and has a low propensity to cause metabolic side effects and prolactin elevation. We recently reported that blonanserin can improve some types of cognitive function associated with prefrontal cortical function in patients with first-episode and chronic schizophrenia. Taken together, these results suggest that blonanserin may be a promising candidate for a first-line antipsychotic for acute and maintenance therapy for schizophrenia. Further comparative studies are warranted to clarify the benefit/risk profile of blonanserin and its role in the treatment of schizophrenia.
Keywords: blonanserin, schizophrenia, pharmacology, pharmacokinetics, efficacy, safety
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.